JP7220653B2 - アルファvインテグリン阻害剤としてのピロールアミド - Google Patents
アルファvインテグリン阻害剤としてのピロールアミド Download PDFInfo
- Publication number
- JP7220653B2 JP7220653B2 JP2019523772A JP2019523772A JP7220653B2 JP 7220653 B2 JP7220653 B2 JP 7220653B2 JP 2019523772 A JP2019523772 A JP 2019523772A JP 2019523772 A JP2019523772 A JP 2019523772A JP 7220653 B2 JP7220653 B2 JP 7220653B2
- Authority
- JP
- Japan
- Prior art keywords
- ethyl
- pyrrole
- naphthyridin
- tetrahydro
- carboxamido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662418833P | 2016-11-08 | 2016-11-08 | |
US62/418,833 | 2016-11-08 | ||
PCT/US2017/060392 WO2018089360A1 (en) | 2016-11-08 | 2017-11-07 | Pyrrole amides as alpha v integrin inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020500182A JP2020500182A (ja) | 2020-01-09 |
JP2020500182A5 JP2020500182A5 (es) | 2020-12-17 |
JP7220653B2 true JP7220653B2 (ja) | 2023-02-10 |
Family
ID=60409438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019523772A Active JP7220653B2 (ja) | 2016-11-08 | 2017-11-07 | アルファvインテグリン阻害剤としてのピロールアミド |
Country Status (22)
Country | Link |
---|---|
US (1) | US10717736B2 (es) |
EP (1) | EP3538528B1 (es) |
JP (1) | JP7220653B2 (es) |
KR (1) | KR102515507B1 (es) |
CN (1) | CN110139864B (es) |
AU (1) | AU2017359030A1 (es) |
BR (1) | BR112019009293A2 (es) |
CA (1) | CA3042693A1 (es) |
CY (1) | CY1123893T1 (es) |
DK (1) | DK3538528T3 (es) |
EA (1) | EA201991124A1 (es) |
ES (1) | ES2852351T3 (es) |
HR (1) | HRP20210228T1 (es) |
HU (1) | HUE053620T2 (es) |
IL (1) | IL266469A (es) |
LT (1) | LT3538528T (es) |
MX (1) | MX2019005233A (es) |
PL (1) | PL3538528T3 (es) |
PT (1) | PT3538528T (es) |
RS (1) | RS61453B1 (es) |
SI (1) | SI3538528T1 (es) |
WO (1) | WO2018089360A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHOD OF USING |
CN110167934B (zh) * | 2016-11-08 | 2022-06-10 | 百时美施贵宝公司 | 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物 |
MX2019007797A (es) | 2016-12-29 | 2019-10-21 | Univ Saint Louis | Antagonistas de integrinas. |
US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
EP3589627A4 (en) | 2017-02-28 | 2020-08-05 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V) (BETA-6) -INTEGRIN |
EP3843727A4 (en) * | 2018-08-29 | 2022-08-17 | Morphic Therapeutic, Inc. | INTEGRIN (ALPHA-V)(BETA-6) INHIBITORS |
MX2021002181A (es) | 2018-08-29 | 2021-07-15 | Morphic Therapeutic Inc | Inhibicion de la integrina alfa v beta 6. |
CN112969687A (zh) | 2018-10-30 | 2021-06-15 | 吉利德科学公司 | 作为α4β7整合素抑制剂的喹啉衍生物 |
WO2020092401A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN |
AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
US11174256B2 (en) | 2018-10-30 | 2021-11-16 | Gilead Sciences, Inc. | Imidazopyridine derivatives |
CA3148613A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001524481A (ja) | 1997-11-26 | 2001-12-04 | デュポン ファーマシューティカルズ カンパニー | αVβ3アンタゴニストとしての1,3,4−チアジアゾール類および1,3,4−オキサジアゾール類 |
JP2002511462A (ja) | 1998-04-10 | 2002-04-16 | ジー・ディー・サール・アンド・カンパニー | ビトロネクチンアンタゴニストとしてのヘテロ環式グリシルβ−アラニン誘導体 |
JP2003507458A (ja) | 1999-08-24 | 2003-02-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 新規なインテグリンαvβ3阻害剤 |
JP2005539049A (ja) | 2002-08-16 | 2005-12-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | インテグリンと選択的に結合するピペリジニル化合物 |
JP2007507440A (ja) | 2003-10-01 | 2007-03-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 抗線維症薬としてのαvβ3及びαvβ6インテグリンアンタゴニスト |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
IL118325A0 (en) * | 1995-05-25 | 1996-10-31 | Pont Merck And Pharmaceutical | Integrin receptor antagonists and pharmaceutical compositions containing them |
ZA972195B (en) | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
WO1999030709A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
EP1105389A4 (en) | 1998-08-13 | 2001-10-17 | Merck & Co Inc | INTEGRIN RECEPTOR ANTAGONISTS |
AUPP646598A0 (en) | 1998-10-12 | 1998-11-05 | Fujisawa Pharmaceutical Co., Ltd. | New processes for producing alpha-alanine derivative |
IL149313A0 (en) * | 1999-11-08 | 2002-11-10 | Merck & Co Inc | Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists |
GB0001447D0 (en) * | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
JP4615826B2 (ja) | 2001-01-29 | 2011-01-19 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 置換インドールおよびインテグリンアンタゴニストとしてのそれらの使用 |
TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
WO2006108040A1 (en) | 2005-04-05 | 2006-10-12 | Janssen Pharmaceutica, N.V. | Substituted indoles and their use as integrin antagonists |
EP2049490A1 (en) | 2006-06-09 | 2009-04-22 | Astra Zeneca AB | N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors |
WO2008125811A1 (en) | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
JP2013517295A (ja) * | 2010-01-19 | 2013-05-16 | セラヴァンス, インコーポレーテッド | 二重に作用するチオフェン、ピロール、チアゾールおよびフラン抗高血圧症薬 |
ITFI20100019A1 (it) | 2010-02-12 | 2011-08-13 | Univ Firenze | Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori. |
CN103038229B (zh) | 2010-05-26 | 2016-05-11 | 桑诺维恩药品公司 | 杂芳基化合物及其使用方法 |
LT2953948T (lt) * | 2013-02-07 | 2018-01-10 | Scifluor Life Sciences, Inc | Fluorinti integrino antagonistai |
GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201417002D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201417094D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
RU2017132433A (ru) | 2015-02-19 | 2019-03-19 | Сайфлуор Лайф Сайенсиз, Инк. | Фторированные производные тетрагидронафтиридинилнонановой кислоты и их применение |
JP2018515424A (ja) | 2015-03-10 | 2018-06-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗アルファvベータ1インテグリン阻害剤及び使用方法 |
-
2017
- 2017-11-07 RS RS20210206A patent/RS61453B1/sr unknown
- 2017-11-07 LT LTEP17801236.5T patent/LT3538528T/lt unknown
- 2017-11-07 MX MX2019005233A patent/MX2019005233A/es active IP Right Grant
- 2017-11-07 JP JP2019523772A patent/JP7220653B2/ja active Active
- 2017-11-07 PL PL17801236T patent/PL3538528T3/pl unknown
- 2017-11-07 KR KR1020197016078A patent/KR102515507B1/ko active IP Right Grant
- 2017-11-07 EA EA201991124A patent/EA201991124A1/ru unknown
- 2017-11-07 SI SI201730618T patent/SI3538528T1/sl unknown
- 2017-11-07 CA CA3042693A patent/CA3042693A1/en not_active Abandoned
- 2017-11-07 WO PCT/US2017/060392 patent/WO2018089360A1/en unknown
- 2017-11-07 DK DK17801236.5T patent/DK3538528T3/da active
- 2017-11-07 US US16/347,826 patent/US10717736B2/en active Active
- 2017-11-07 HU HUE17801236A patent/HUE053620T2/hu unknown
- 2017-11-07 EP EP17801236.5A patent/EP3538528B1/en active Active
- 2017-11-07 ES ES17801236T patent/ES2852351T3/es active Active
- 2017-11-07 CN CN201780082138.2A patent/CN110139864B/zh active Active
- 2017-11-07 PT PT178012365T patent/PT3538528T/pt unknown
- 2017-11-07 AU AU2017359030A patent/AU2017359030A1/en not_active Abandoned
- 2017-11-07 BR BR112019009293A patent/BR112019009293A2/pt not_active Application Discontinuation
-
2019
- 2019-05-06 IL IL266469A patent/IL266469A/en unknown
-
2021
- 2021-02-09 HR HRP20210228TT patent/HRP20210228T1/hr unknown
- 2021-02-23 CY CY20211100149T patent/CY1123893T1/el unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001524481A (ja) | 1997-11-26 | 2001-12-04 | デュポン ファーマシューティカルズ カンパニー | αVβ3アンタゴニストとしての1,3,4−チアジアゾール類および1,3,4−オキサジアゾール類 |
JP2002511462A (ja) | 1998-04-10 | 2002-04-16 | ジー・ディー・サール・アンド・カンパニー | ビトロネクチンアンタゴニストとしてのヘテロ環式グリシルβ−アラニン誘導体 |
JP2003507458A (ja) | 1999-08-24 | 2003-02-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 新規なインテグリンαvβ3阻害剤 |
JP2005539049A (ja) | 2002-08-16 | 2005-12-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | インテグリンと選択的に結合するピペリジニル化合物 |
JP2007507440A (ja) | 2003-10-01 | 2007-03-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 抗線維症薬としてのαvβ3及びαvβ6インテグリンアンタゴニスト |
Also Published As
Publication number | Publication date |
---|---|
IL266469A (en) | 2019-07-31 |
CN110139864A (zh) | 2019-08-16 |
US20190256512A1 (en) | 2019-08-22 |
MX2019005233A (es) | 2019-08-12 |
PL3538528T3 (pl) | 2021-05-31 |
WO2018089360A1 (en) | 2018-05-17 |
HUE053620T2 (hu) | 2021-07-28 |
US10717736B2 (en) | 2020-07-21 |
HRP20210228T1 (hr) | 2021-03-19 |
RS61453B1 (sr) | 2021-03-31 |
JP2020500182A (ja) | 2020-01-09 |
BR112019009293A2 (pt) | 2019-07-30 |
CY1123893T1 (el) | 2022-05-27 |
EA201991124A1 (ru) | 2019-10-31 |
CA3042693A1 (en) | 2018-05-17 |
KR102515507B1 (ko) | 2023-03-28 |
AU2017359030A1 (en) | 2019-06-20 |
EP3538528B1 (en) | 2020-12-23 |
PT3538528T (pt) | 2021-02-16 |
KR20190076031A (ko) | 2019-07-01 |
DK3538528T3 (da) | 2021-02-15 |
EP3538528A1 (en) | 2019-09-18 |
ES2852351T3 (es) | 2021-09-13 |
CN110139864B (zh) | 2022-08-23 |
SI3538528T1 (sl) | 2021-03-31 |
LT3538528T (lt) | 2021-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7220653B2 (ja) | アルファvインテグリン阻害剤としてのピロールアミド | |
US11639353B2 (en) | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | |
US11028071B2 (en) | Indazole derivatives as alpha v integrin antagonists | |
JP7128811B2 (ja) | アルファvインテグリン阻害剤としてのアゾールアミドおよびアミン | |
US10968219B2 (en) | 3-substituted propionic acids as αV integrin inhibitors | |
JP2024508924A (ja) | Clostridium difficileの治療において有用なジアゼピン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201106 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201106 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210916 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211012 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220531 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220831 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230117 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230131 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7220653 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |